Theranos

Theranos was built on a compelling vision: making blood testing cheap, fast, and painless. Elizabeth Holmes, often styled as the female Steve Jobs, promised that the 'Edison'—a portable analyzer—could perform over 200 medical tests from a tiny finger-prick sample. This was marketed as a disruption to the $75 billion laboratory industry dominated by giants like Quest and LabCorp. The Technology That Never Was The fundamental problem was physics. Diluting a single drop of blood to run hundreds of tests introduces massive margins of error. Behind the scenes, the Edison was a failure—it often overheated, broke down, and produced wildly inconsistent results. To hide this, Theranos secretly used industry-standard Siemens machines to run the majority of its tests, even for the samples collected at Walgreens Wellness Centers. The Whistleblowers and the WSJ The house of cards began to tumble in October 2015, when Wall Street Journal reporter John Carreyrou published a scathing exposé. His investigation was aided by brave whistleblowers—most notably Erika Cheung and Tyler Shultz (grandson of board member George Shultz)—who risked legal intimidation to reveal that the company was faking demos and providing patients with inaccurate, potentially dangerous medical data. The Legal Reckoning By 2016, Theranos was forced to void or correct two years' worth of blood test results. The company faced a barrage of lawsuits from patients, investors, and partners (Safeway and Walgreens both dissolved their $350M+ deals). In 2018, the SEC charged the company with 'massive fraud,' and a federal grand jury indicted Holmes and Balwani. The Aftermath Theranos officially ceased operations in September 2018, liquidating its remaining assets to pay creditors. In 2022, Elizabeth Holmes was sentenced to 11 years and 3 months in prison, while Sunny Balwani received 12 years and 11 months. The scandal remains the most famous cautionary tale of the 21st-century startup era, proving that in medicine, branding cannot replace biochemistry.